Songkun Gao

Mr. Songkun Gao


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
SGSongkun Gao
Songkun Gao
JWJinhua Wang
Jinhua Wang
ZLZhongxian Li
Zhongxian Li
TWTong Wang
Tong Wang
JWJiandong Wang
Jiandong Wang
Purpose: To describe the temporal trend of endometrial burden in postmenopausal women aged 55 years and above worldwide from 1990 to 2021, evaluate the age cohort effect, explore its influencing factors, and predict the disease burden in the next 15 years. Patients and Methods: Using Joinpoint regression, data from the 2021 Global Burden of Disease Study were assessed for changes in endometrial cancer incidence rate, morbidity, and mortality in postmenopausal women aged 55 years and above. Age period cohort analysis helped estimate age, period, and cohort effects. The Das Gupta method helped analyze effects of different factors on endometrial cancer incidence and mortality among postmenopausal patients. ARIMA helped predict the endometrial cancer disease burden in postmenopausal women from 2022 to 2036. Results: In 2021, globally, there were 360253 (326,176– 388545) cases and 84630 (75,523– 93215) deaths among postmenopausal patients with endometrial cancer. During 1990– 2021, the global endometrial cancer incidence in postmenopausal women gradually increased, while the mortality rate gradually decreased. Changes in disease incidence and mortality rates are mainly due to population growth and epidemiological changes, with little influence of age. The risk of endometrial cancer in postmenopausal women gradually increased with age, using age, period, and cohort average as the reference groups. The mortality rate decreased gradually decreased in 2019 and continued to rise thereafter. It is expected that by 2036, the incidence of endometrial cancer in postmenopausal women aged 55 years and above will increase by 6.5%, and the mortality rate will decrease by 8.0%. Conclusion: The number of patients with postmenopausal endometrial cancer aged 55 years and above is still increasing, and it is necessary to establish a comprehensive screening and treatment mechanism to ensure prolongation of patient lifespan.

1 December 2024 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
SGSongkun Gao
Songkun Gao
JWJinhua Wang
Jinhua Wang
TWTong Wang
Tong Wang
JWJiandong Wang
Jiandong Wang
Purpose: To evaluate the insulin resistance in patients with menopause who were newly diagnosed with endometrial cancer and its association with disease development. Methods: The study included 356 patients with menopause who underwent hysteroscopy at Beijing Obstetrics and Gynecology Hospital between September 2013 and July 2018. Data on age, height, weight, menarche and menopausal age, pregnancies, births, and family history of tumors, hypertension, and diabetes were collected. Blood tests provided fasting blood glucose, triglycerides, total cholesterol, high-density lipoprotein, and low-density lipoprotein levels. Pathological testing determined whether patients had endometrial cancer or precancerous lesions. Differences in influencing factors between patients with endometrial cancer or precancerous lesions and those with normal or benign conditions were analyzed using univariate analysis. Quartile grouping of the Metabolic Score for Insulin Resistance (METS-IR) and Triglyceride-Glucose (TyG) index were applied to examine the impact of different insulin resistance on the development of endometrial cancer or precancerous lesions. Results: Univariate analysis revealed that the proportion of patients with hypertension and diabetes was significantly higher among those with endometrial cancer and precancerous lesions. METS-IR and TyG levels were significantly increased in patients with endometrial cancer and precancerous lesions. The quartile grouping results of METS-IR and TyG suggested that age, BMI, FBG, TG, hypertension, and diabetes prevalence rates increased with an increase in METS-IR or TyG, whereas lipid indicators were negatively correlated and unstable Logistic regression suggested that none of the above influencing factors and METS-IR or TyG were related to the pathological results of the patients. Conclusion: Patients with endometrial or precancerous lesions showed evidence of insulin resistance compared to others, though this was not directly associated with disease presence. This study provides relevant information for preventing of endometrial cancer in the future. Larger studies are needed to evaluate the role of METS-IR and TyG in endometrial cancer prevention.

1 November 2023 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
SGSongkun Gao
Songkun Gao
LHLei Huang
Lei Huang
TWTong Wang
Tong Wang
JWJiandong Wang
Jiandong Wang
Purpose: Investigation of HPV infection treatment in women undergoing cervical cold-knife conization for advanced cervical intraepithelial neoplasia. Patients and Methods: A retrospective analysis was conducted on patients who underwent cervical cold-knife conization for cervical intraepithelial neoplasia grade II–III at Beijing Obstetrics and Gynecology Hospital from January 2017 to December 2018. The HPV infection status of the patients at 6 months, 1 year, and 2 years after surgery was collected. We use chi square analysis and binary logistic regression to evaluate various factors such as age, number of pregnancies, number of cesarean sections, number of vaginal deliveries, HPV type, size of surgical specimens (diameter and height), and the influence of specimen edge on HPV infection. Results: A total of 334 patients were included in the analysis. The patients are mainly infected with HPV 16/58/52. Age is a influencing factor for HPV recovery 12 months after CKC surgery (P=0.002). Based on the diagnosis of HPV one year after CKC, the recovery rate of HPV58 patients is significantly lower than HPV16. Age is a influencing factor for the recovery of HPV infection (P< 0.05). Conclusion: The treatment of HPV infection by CKC is related to the patient’s age and HPV subtype but not to number of pregnancies, number of pregnancies, number of vaginal deliveries, size of surgical specimens, and marginal conditions. The rate of HPV negative conversion is relatively high 24 months after the patient does not undergo surgery, but there is currently a lack of data on cervical lesions that match HPV results.

1 April 2024 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
HGHuimin Guo
Huimin Guo
SGSongkun Gao
Songkun Gao
WKWeimin Kong
Weimin Kong
Objective: In current most observational studies, the prognosis of cervical adenocarcinoma is worse than that of cervical squamous cell carcinoma. However, most of the current studies are holistic and lack more detailed staging and grouping analysis of the prognosis of the two types of cervical tumors. Patients and Methods: Inclusion from the SEER database of stage IIB-IVA cervical squamous cell carcinoma and cervical adenocarcinoma patients who did not undergo surgery from 2000 to 2019, underwent radiotherapy/chemotherapy/radiotherapy and chemotherapy/no treatment, and then propensity score matching (PSM) was performed to eliminate confounding factors between cervical squamous cell carcinoma and cervical adenocarcinoma patients with the same stage and treatment method. After matching the original data and propensity score, logarithmic rank test and chi square test were used to evaluate the survival benefits of different stages and treatment methods for patients using Kaplan Meier curve. The prognosis of two types of cervical tumors under the same treatment method was compared, and factors that may cause poor prognosis were analyzed, excluding confounding factors. Results: A total of 10,057 patients were included in this study, and survival analysis showed a significant correlation between the treatment method used and patient prognosis (P< 0.05). However, for patients who received radiotherapy or no special treatment, OS and CSS were only related to tumor stage and not to tumor type. In patients undergoing radiotherapy and chemotherapy, the OS and CSS of stage IIIA and IVA patients are not related to tumor pathological characteristics, while the OS of stage IIB patients is not related to tumor properties after PSM. Conclusion: In patients undergoing radiotherapy and chemotherapy, the OS and CSS of stage IIIA and IVA patients were not related to histological type, while the OS of stage IIB patients was not related to histological type after PSM.

28 November 2024 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
TWTong Wang
Tong Wang
NJNingyi Jia
Ningyi Jia
SGSongkun Gao
Songkun Gao
SLShengjie Liu
Shengjie Liu
MLMing Liu
Ming Liu
HZHong Zhang
Hong Zhang
Objective: This study aims to demonstrate that the EN2 protein in cervical mucus may serve as a novel biomarker for screening endometrial cancer. Materials and Methods: This study included 133 patients who were treated at Beijing Obstetrics and Gynecology Hospital. According to the pathological results of hysteroscopy endometrial biopsy, the patients were divided into endometrial cancer group (n = 55), endometrial atypical hyperplasia group (n = 16), benign lesion group (n = 28), and control group (n = 34). All patients collected cervical mucus before hysteroscopy, and the level of EN2 protein in cervical mucus was detected by ELISA in the four groups of patients. Nine patients who underwent surgical treatment for endometrial cancer were included, and endometrial cancer lesions and adjacent tissues without endometrial cancer infiltration were taken from the endometrial cancer lesions and cervical tissues. Fifteen patients who underwent hysterectomy for benign lesions were included, and endometrial and cervical tissues were taken from the endometrial cancer lesions and adjacent tissues without endometrial cancer infiltration. PT-PCR, immunohistochemistry, and WB were used to verify the expression differences of EN2 protein in cancerous lesions and endometrial tissues without endometrial infiltration, cervical tissues, and endometrial tissues without endometrial lesions. In addition, HEC1B, KLE, and HeLa cell lines were used to characterize EN2 overexpression in endometrial cancer cells. Immunohistochemistry, RT-PCR, and confocal analysis were used to detect the expression of EN2 protein in different cell lines. Results: In different groups, the average concentration of EN2 protein in cervical mucus in the EC group was significantly higher than that in the benign group and the normal control group (573.9 ± 123.4 ng/mL vs 153.5 ± 106.2 ng/mL and 153.0 ± 107.5 ng/mL, P < 0.001). The concentration of EN2 protein in EIN3 case specimens was significantly higher than that in the normal control group (P < 0.001). ROC analysis showed that the optimal threshold for diagnosing endometrial cancer in cervical mucus was 321.1 ng/ml, with a sensitivity of 92.6% and specificity of 95.4% for distinguishing EINIII, EC, and non-cancerous cases. In clinical specimens, the expression level of EN2 protein in endometrial cancer tissues was significantly higher than that in endometrial tissues and cervical tissues without endometrial cancer infiltration. In addition, PT-PCR, immunohistochemistry, suggest that EN2 protein is overexpressed in endometrial cancer cell lines compared to cervical adenocarcinoma cells (P < 0.01). Conclusion: The concentration of EN2 protein in cervical mucus can effectively identify endometrial cancer and precancerous lesions. The increased expression of EN2 protein in endometrial cancer lesions leads to an increase in the concentration of EN2 protein in the cervical mucus of endometrial cancer patients.This is a small single-center study, and larger studies are needed to determine the role of EN2 protein in the diagnosis of endometrial cancer.

1 July 2025 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
SGSongkun Gao
Songkun Gao
FLFengshuang Li
Fengshuang Li
FSFang Song
Fang Song
XZXiaofeng Zhang
Xiaofeng Zhang
YHYue He
Yue He
JWJiandong Wang
Jiandong Wang
Objective: To evaluate the differences in efficacy between polyvinyl alcohol colorless embolic microspheres (8Spheres®) and gelatin embolic microspheres (Embosphere®) in uterine artery embolization for symptomatic uterine fibroids. Methods: We included 259 patients from 12 hospitals who underwent uterine artery embolization for symptomatic uterine fibroids. We collected preoperative general conditions, menstrual status, and uterine and fibroid sizes as indicated by magnetic resonance imaging, as well as changes in ovarian hormone levels before and 6 months after the procedure. Differences in uterine fibroid scores and health-related quality of life scores between the two types of microspheres were compared using analysis of covariance (ANCOVA). Differences in the largest fibroid volume, uterine volume, total menstrual bleeding score, and ovarian hormone levels were compared using T-tests or Mann–Whitney U-tests. Results: There was no significant difference in clinical efficacy between the two types of microspheres at 6 months postoperatively (P=0.4081). No significant differences were observed in uterine fibroid volume or symptom-related scores.There were no significant differences in ovarian hormone levels between the two groups or within each group before and after the procedure. Conclusion: The use of 8Spheres® is effective for symptomatic uterine fibroids and is comparable to the currently clinically used Embosphere® microspheres in terms of efficacy for symptomatic uterine fibroids.